With concern already growing about a possible third wave of COVID-19 infections, the UK has cleared the use of a fourth vaccine from Johnson & Johnson's Janssen division.
Belgium's Ministry of Health has paused dosing of people under the age of 41 with Johnson & Johnson's one-shot COVID-19 vaccine, following the death of a woman from what appeared to be
With the ink barely dry on the FDA's approval of Johnson & Johnson's Rybrevant, its first bispecific antibody for cancer, the drugmaker is already showcasing others in its pipeline.
Johnson & Johnson's Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
All seven COVID-19 vaccines ordered by the UK government will be tested in a new trial that will see whether they can be used as a third booster dose to protect against new variants.
Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb.